Filtered By:
Condition: Headache
Management: Contracts
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Q & A: What you should know about new COVID vaccines for young kids
Vaccines against COVID-19 are finally available for the youngest Americans.The U.S. Food and Drug Administration voted on June 17 to authorize shots from Moderna and Pfizer for children as young as 6 months. The vaccines are rolling out across the country, including at UCLA Health, making vaccine-induced immunity against coronavirus available for the first time to children younger than 5.“It’s great news as many people are looking forward to summer vacations and getting together with family,” saidDr. Annabelle de St. Maurice, a pediatrician and co-chief infection prevention officer for UCLA Health. “Both vaccines h...
Source: UCLA Newsroom: Health Sciences - June 29, 2022 Category: Universities & Medical Training Source Type: news
Understanding omicron, the new COVID-19 variant
Countries around the world are making preparations against omicron, a new variant of the novel coronavirus that causes COVID-19. Although it hasn ’t yet been detected in the United States (as of Nov. 29, 2021), health officials are once again cautioning the public about getting vaccinated, frequent testing and potentially stepping up tried-and-true measures to prevent transmission such as mask-wearing and hand-washing.We spoke with Shangxin Yang, a pathologist at UCLA Health, about the new variant and what everyone needs to know.How is the omicron variant different from the delta variant and others?It has a lot of mut...
Source: UCLA Newsroom: Health Sciences - November 30, 2021 Category: Universities & Medical Training Source Type: news
One in ten children infected with COVID-19 will suffer from 'long Covid' after they recover
More than 11% of children who contract coronavirus will develop 'long Covid', the Israeli Health Ministry reports. The condition can cause frequent fatigue and chronic headaches for children.
Source: the Mail online | Health - September 15, 2021 Category: Consumer Health News Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced an immune respons...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
2020 reflections: Bruins respond to the challenges of COVID-19
When people look back, COVID-19 will be what defines 2020 — and that applies to UCLA, just like everywhere else. From forcing us to shift to remote learning, move all but the most essential jobs off campus and ultimately close the campus to the public, the pandemic remade life in ways we couldn’t have imagined.But as difficult as the challenges were, Bruins everywhere responded withthe resilience, creativity and ingenuity that embody our values.Scientists, doctors and scholars continued to pursue the research that helped the public better understand the virus.Health care workers put themselves on the line day after day...
Source: UCLA Newsroom: Health Sciences - December 16, 2020 Category: Universities & Medical Training Source Type: news
Common cold, flu, or coronavirus?
In the early days of the outbreak, the novel coronavirus (COVID-19) was repeatedly compared to the flu (influenza) and even to the common cold (rhinoviruses, et al). This was due to an initial impression of shared symptoms.
The differences between these conditions are particularly important as we kick off National Influenza Vaccination Week (NIVW) and the ‘flu season’. So, how can we tell which of these diseases we are dealing with in a given patient?
Common cold
Let’s start with the common cold, a condition that can be caused by over 200 different strains of viruses. On average, an adult wil...
Source: GIDEON blog - December 8, 2020 Category: Databases & Libraries Authors: Kristina Symes Tags: Diagnosis Identify News Source Type: blogs
COVID-19 Vaccines Are Coming. Here ’s What to Expect
Vaccines normally take decades to develop and test, but two COVID-19 shots, from Moderna and Pfizer (in partnership with BioNTech), have gone from nonexistent to about 95% effectiveness in 10 months. Public-health officials and governments now have the dual challenge of convincing the public that the vaccines are both safe and scientifically sound, as well as figuring out how to distribute billions of doses. Here’s what we know so far about how that’s going.
When can I get vaccinated?
That depends.
Manufacturers have already begun producing vaccines, betting that they will be effective, so they can be ready to ...
Source: TIME: Science - November 19, 2020 Category: Science Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Why Tick Season Could Be Worse In The Summer Of COVID-19
(CNN) — After more than three months of shutdowns, mandatory quarantines, self-imposed exile from society and working from home, nature-lovers looking for a well-earned breath of fresh air could face a possible collision course between coronavirus and tick-borne illnesses this summer.
A “perfect storm,” warns Eva Sapi, a University of New Haven biology professor and group director for the Lyme Disease Research Group.
Noting the mild winter on the East Coast, Sapi says, “We do have a bad year for the ticks.”
Hikers, campers and anyone else eager for an escape could “just explode into the...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 7, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated CBSN Boston CNN LYME DISEASE tick season ticks Source Type: news
Medical and Paramedical Care of Patients With Cerebellar Ataxia During the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19 Cerebellum Task Force
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the cause of the current pandemic coronavirus disease 2019 (COVID-19), primarily targets the respiratory system. Some patients also experience neurological signs and symptoms ranging from anosmia, ageusia, headache, nausea, and vomiting to confusion, encephalitis, and stroke. Approximately 36% of those with severe COVID-19 experience neurological complications. The virus may enter the central nervous system through the olfactory nerve in the nasal cavity and damage neurons in the brainstem nuclei involved in the regulation of respiration. Patients with cerebe...
Source: Frontiers in Neurology - May 21, 2020 Category: Neurology Source Type: research
